ReviewCalcified tissue international2016
Sclerostin Inhibition in the Management of Osteoporosis.
Review in Calcified tissue international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 76 citations in OpenAlex.
- Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Trial
- Bispecific antibody against sclerostin and DKK1 improves bone health and reduces bone marrow adipose tissue accumulation in experimental chronic kidney disease.Bone research · 2026Article
- Multimodal imaging fusion and machine learning model development: differential diagnosis of spinal inflammatory lesions using combined CT hounsfield units and MRI features.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- In silico identification of sclerostin inhibitors.Molecular diversity · 2026Article
- Comparative safety of denosumab and romosozumab in osteoporosis: an analysis based on the FDA adverse event reporting system database.Frontiers in medicine · 2026Article
- Article
- The link between osteoporosis and cardiovascular diseases: a review of shared mechanisms, risk factors, and therapeutic approaches.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025Review
- Review of osteokines in spinal cord injury: potential biomarkers during rehabilitation.Journal of orthopaedic surgery and research · 2025Review
- The Effects of Switch Therapy in Osteoporosis Treatment after Romosozumab after Comparing with Prior Treatment.Journal of osteoporosis · 2024Article
- Elevated plasma sclerostin is associated with high brain amyloid-β load in cognitively normal older adults.npj aging · 2023Article
- Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.Molecular cancer · 2022Article
- Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.Journal of endocrinological investigation · 2022Observational
- The osteocyte as a signaling cell.Physiological reviews · 2022Review
- Aging of Skeletal Stem Cells.Advances in geriatric medicine and research · 2022Article
- Differential bone remodeling mechanism in hindlimb unloaded rats and hibernating Daurian ground squirrels: a comparison between artificial and natural disuse.Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2021Article
- Sclerostin: from bench to bedside.Journal of bone and mineral metabolism · 2021Review
- Romosozumab: A Review in Postmenopausal Osteoporosis.Drugs & aging · 2020Review
- Review
- WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders.Frontiers in endocrinology · 2020Review
- The Genetic Architecture of High Bone Mass.Frontiers in endocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recognition of the importance of the Wnt-signaling pathway in bone metabolism and studies of patients with rare skeletal disorders characterized by high bone mass identified sclerostin as target for the development of new therapeutics for osteoporosis. Findings in animals and humans with sclerostin deficiency as well as results of preclinical and early clinical studies with sclerostin inhibitors demonstrated a new treatment paradigm with a bone building agent for the management of patients with osteoporosis, the antifracture efficacy, and long-term tolerability of which remain to be established in on-going phase III clinical studies. In this article we review the currently available preclinical and clinical evidence supporting the use of sclerostin inhibitors in osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.